Biotech Has Been Polarizing For Hedge Funds, But This Venture Capitalist Sees Opportunities – ValueWalk Premium
Biotech

Biotech Has Been Polarizing For Hedge Funds, But This Venture Capitalist Sees Opportunities

Biotech was a hot sector in 2020, but it plunged in early 2021 along with the rest of the market, as demonstrated by the performance of the SPDR S&P Biotech ETF. As a subsector of healthcare and technology, many fund managers have an extreme position on biotech that runs on either the long or short side. However, others won't touch it at all.

At MarketWatch's Best New Ideas Money Festival on Wednesday, venture capitalist Deena Shakir of Lux Capital talked about the latest technologies in healthcare and companies that are helping people live healthier lives.

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk